Evidence map›Paper›PMID 21606604›Full record

ArticleThe Journal of clinical investigation2011

From probiotics to therapeutics: another step forward?

Fayez K Ghishan, Pawel R Kiela

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical investigation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Effect of DailyMedicina (Kaunas, Lithuania) · 2025
    Trial
  2. Review
  3. Gut microbes
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Fayez K GhishanDepartment of Pediatrics, Steele Children's Research Center, University of Arizona Health Sciences Center, Tucson, Arizona 85724, USA. fghishan@peds.arizona.edu
Pawel R Kiela
Children's Center · USUniversity of Arizona · US

Funding

DEVELOPMENT OF INTESTINAL ION TRANSPORTR01DK041274 · NIDDK · VANDERBILT UNIVERSITY · PI GHISHAN, FAYEZ KHALAF, KIELA, PAWEL R · 1988 to 2016
$5.5M
Intestinal Barrier Function: Protective Effects of CurcuminR01DK067286 · NIDDK · UNIVERSITY OF ARIZONA · PI GHISHAN, FAYEZ KHALAF, KIELA, PAWEL R · 2005 to 2013
$2.6M
NIDDK NIH HHS 2R01DK041274NIDDK NIH HHS 5R01DK067286NIDDK NIH HHS R01 DK041274NIDDK NIH HHS R01 DK067286
6 · The paper itself

Abstract

Preclinical studies with probiotics continue to unravel mechanisms of cytoprotection and suggest that approaches utilizing microbial products as therapeutics in acute and chronic gastrointestinal disorders could be effective. However, clinical trials using these bacteria have thus far been inconsistent. In this issue of the JCI, Yan et al. describe a novel mechanism of cytoprotection by p40, a soluble product of Lactobacillus rhamnosus GG, mediated via EGFR. The efficacy of p40 in three models of chemically induced colitis indicates tremendous therapeutic potential, though this finding will need to be verified in human patients.

Indexed as

MetagenomeAnimalsBacterial ProteinsColitisDrug Evaluation, PreclinicalEnzyme ActivationErbB ReceptorsFood MicrobiologyGastrointestinal DiseasesHumansInflammatory Bowel DiseasesLacticaseibacillus rhamnosusMiceMicrobial ConsortiaMicrobial InteractionsOpportunistic InfectionsBacterial ProteinsEGFR protein, mouseErbB Receptorsp40 protein, Lactobacillus rhamnosusProtein KinasesRecombinant Proteins

Identifiers

PMID21606604
PMCPMC3104781
OpenAlexW2140144550

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.